allogene.com

Website beoordeling allogene.com

Home - Allogene

 Gegenereerd op April 10 2026 06:02 AM

Oude statistieken? UPDATE !

De score is 49/100

SEO Content

Title

Home - Allogene

Lengte : 15

Perfect, uw title tag bevat tussen de 10 en 70 karakters.

Description

Lengte : 0

Erg slecht.we hebben geen meta description gevonden in uw website. Gebruik deze gratis online meta tags generator om een beschrijving te genereren.

Keywords

Erg slecht. We hebben geen meta keywords gevonden in uw website. Gebruik deze gratis online meta tags generator om keywords te genereren.

Og Meta Properties

Goed, uw page maakt gebruik van Og Properties.

Property Content
locale en_US
type website
title Home - Allogene
description REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T PRODUCT PLATFORM INNOVATION Multiplex gene-engineering and gene-editing capabilities Proprietary lymphodepletion platform State-of-the-art manufacturing Opportunity for product optimization SEE OUR PIONEERING PLATFORM >> KEY PROGRAMS Cemacabtagene ansegedleucel (cema-cel): Frontline treatment in LBCL, including diffuse large B-cell lymphoma (DLBCL) ALLO-316: ccRCC ALLO-329: autoimmune disease EXPLORE OUR PIPELINE >> LEADERSHIP A […]
url https://allogene.com/
site_name Allogene
image https://allogene.com/wp-content/uploads/2021/09/innovation.png

Headings

H1 H2 H3 H4 H5 H6
4 10 21 0 0 0
  • [H1] RESOLUTION
  • [H1] REDEFINING THE FUTURE OF CAR T
  • [H1] RESOLUTION
  • [H1] REDEFINING THE FUTURE OF CAR T
  • [H2] NOW ENROLLING
  • [H2] NOW ENROLLING
  • [H2] Now Enrolling
  • [H2] NOW ENROLLING
  • [H2] REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T PRODUCT PLATFORM
  • [H2] WE DON’T JUST SEE THE FUTURE.
  • [H2] WE KNOW HOW TO GET THERE.
  • [H2] WHY ALLOGENEIC CELL PRODUCTS HAVE THE POTENTIAL TO DO WHAT NO AUTOLOGOUS CAR T HAS DONE BEFORE
  • [H2] OUR PARTNERS
  • [H2] LATEST NEWS
  • [H3] INNOVATION
  • [H3] KEY PROGRAMS
  • [H3] LEADERSHIP
  • [H3] ACCESS
  • [H3] COST
  • [H3] SPEED/RELIABILITY
  • [H3] INNOVATION
  • [H3] Mar 12, 2026
  • [H3] Mar 2, 2026
  • [H3] Feb 5, 2026
  • [H3] Jan 8, 2026
  • [H3] Dec 15, 2025
  • [H3] Nov 10, 2025
  • [H3] Nov 6, 2025
  • [H3] Nov 3, 2025
  • [H3] Oct 30, 2025
  • [H3] Aug 27, 2025
  • [H3] Aug 13, 2025
  • [H3] Aug 6, 2025
  • [H3] CONNECT
  • [H3] CONNECT

Afbeeldingen

We vonden 18 afbeeldingen in de pagina.

3 alt attributen ontbreken. Voeg alternatieve text toe zodat zoekmachines beter kunnen beoordelen wat het onderwerp van de afbeeldingen is.

Text/HTML Ratio

Ratio : 1%

De ratio van text tot HTML code is below 15 procent, dit betekent dat uw pagina waarschijnlijk meer tekst nodig heeft.

Flash

Perfect, geen Flash content gevonden in uw website.

Iframe

Perfect, er zijn geen Iframes in uw website aangetroffen.

Herschreven URL

Perfect. Uw links zien er vriendelijk uit!

Underscores in de URLs

Perfect! Geen underscores gevonden in uw URLs.

In-page links

We vonden een totaal van 71 links inclusie 0 link(s) naar bestanden

Ankertekst Type samenstelling
Skip to content Intern doFollow
CONTACT US Intern doFollow
CAREERS Intern doFollow
PIPELINE Intern doFollow
AlloCAR T PRODUCT PIPELINE Intern doFollow
THE ALPHA3 TRIAL Intern doFollow
THE RESOLUTION TRIAL Intern doFollow
DATABRIEF Intern doFollow
EXPANDED ACCESS Intern doFollow
SCIENCE Intern doFollow
NEXT REVOLUTION IN CELL THERAPY Intern doFollow
PLATFORM FOR TOMORROW Intern doFollow
ON-DEMAND AVAILABILITY Intern doFollow
SCIENTIFIC PUBLICATIONS Intern doFollow
ABOUT US Intern doFollow
AT A GLANCE Intern doFollow
MANAGEMENT TEAM Intern doFollow
BOARD OF DIRECTORS Intern doFollow
SCIENTIFIC ADVISORS Intern doFollow
PARTNERS Intern doFollow
CORPORATE RESPONSIBILITY Intern doFollow
NEWS CENTER Intern doFollow
PRESS RELEASES Intern doFollow
EVENTS Intern doFollow
PERSPECTIVES Intern doFollow
SOCIAL MEDIA Intern doFollow
COMMUNITY GUIDELINES Intern doFollow
INVESTORS Intern doFollow
NEWS & EVENTS Intern doFollow
PRESS RELEASES Intern doFollow
EVENTS Intern doFollow
PRESENTATIONS Intern doFollow
STOCK QUOTE & CHART Intern doFollow
HISTORIC PRICE LOOKUP Intern doFollow
INVESTMENT CALCULATOR Intern doFollow
DOCUMENTS & CHARTERS Intern doFollow
BOARD OF DIRECTORS Intern doFollow
MANAGEMENT Intern doFollow
COMMITTEE COMPOSITION Intern doFollow
SEC FILINGS Intern doFollow
INVESTOR FAQs Intern doFollow
EMAIL ALERTS Intern doFollow
IR INQUIRY Intern doFollow
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update Intern doFollow
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update Intern doFollow
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences Intern doFollow
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T Intern doFollow
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis Intern doFollow
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences Intern doFollow
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update Intern doFollow
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting Intern doFollow
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update Intern doFollow
Allogene Therapeutics Announces Participation in Upcoming Investor Conference Intern doFollow
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update Intern doFollow
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update Intern doFollow
View Map Intern doFollow
Contact Us Intern doFollow
PIPELINE Intern doFollow
AlloCAR T Product Pipeline Intern doFollow
Expanded Access Intern doFollow
Scientific Publications Intern doFollow
At a Glance Intern doFollow
Management Team Intern doFollow
Press Releases Intern doFollow
Events Intern doFollow
Perspectives Intern doFollow
Social Media Intern doFollow
Corporate Governance Intern doFollow
INVESTORS Intern doFollow
TERMS OF USE Intern doFollow
PRIVACY NOTICE Intern doFollow

SEO Keywords

Keywords Cloud

learn allogene cell allogeneic car trial management events therapeutics more

Keywords Consistentie

Keyword Content Title Keywords Description Headings
learn 17
more 16
allogene 12
therapeutics 12
cell 10

Bruikbaarheid

Url

Domein : allogene.com

Lengte : 12

Favicon

Goed, uw website heeft een favicon.

Printbaarheid

Jammer. We vonden geen Print-Vriendelijke CSS.

Taal

Goed. Uw ingestelde taal is en.

Dublin Core

Deze pagina maakt geen gebruik van Dublin Core.

Document

Doctype

HTML 5

Encoding

Perfect. Uw ingestelde Charset is UTF-8.

W3C Validiteit

Fouten : 0

Waarschuwingen : 0

E-mail Privacy

Waarschuwing! Er is op zijn minst 1 e-mailadres gevonden als platte tekst. (voorkom spam!). Gebruik deze gratis antispam protector om e-mailadressen te verbergen voor spammers.

Niet ondersteunde HTML

Geweldig! We hebben geen niet meer ondersteunde HTMl tags gevonden in uw HTML.

Speed Tips

Geweldig, uw website heeft geen tabellen in een tabel.
Jammer, uw website maakt gebruik van inline styles.
Jammer, uw website heeft teveel CSS bestanden (meer dan 4).
Jammer, uw website heeft teveel JS bestanden (meer dan 6).
Perfect, uw website haalt voordeel uit gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Optimalisatie

XML Sitemap

Geweldig, uw website heeft een XML sitemap.

https://allogene.com/sitemap_index.xml

Robots.txt

https://allogene.com/robots.txt

Geweldig uw website heeft een robots.txt bestand.

Analytics

Perfect, uw website heeft een analytics tool.

   Google Analytics

PageSpeed Insights


Device
Categorieën

Free SEO Testing Tool

Website review is een gratis tool waarmee u eenvoudig uw website kunt analyseren